Indications
Lemtrada is indicated for adult patients with relapsing-remitting multiple sclerosis (RRMS) with active disease defined by clinical or imaging features.
Composition
- Active substance
- alemtuzumab
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Lemtrada
- Active substance
- alemtuzumab
- ATC code
- L04AA34
- Therapeutic area
- Multiple Sclerosis
- Marketing authorisation holder
- Sanofi Belgium
- Status
- Authorised
- EU authorisation
- 12 Sept 2013